Visfatin/Nampt: An Adipokine with Cardiovascular Impact

Adipose tissue is acknowledged as an endocrine organ that releases bioactive factors termed adipokines. Visfatin was initially identified as a novel adipokine with insulin-mimetic properties in mice. This adipokine was identical to two previously described molecules, namely, pre-B cell colony-enhanc...

Full description

Bibliographic Details
Main Authors:	Romacho, Tania, Sánchez-Ferrer, Carlos F., Peiró, Concepción
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697395/

id	pubmed-3697395
recordtype	oai_dc
spelling	pubmed-36973952013-07-10 Visfatin/Nampt: An Adipokine with Cardiovascular Impact Romacho, Tania Sánchez-Ferrer, Carlos F. Peiró, Concepción Review Article Adipose tissue is acknowledged as an endocrine organ that releases bioactive factors termed adipokines. Visfatin was initially identified as a novel adipokine with insulin-mimetic properties in mice. This adipokine was identical to two previously described molecules, namely, pre-B cell colony-enhancing factor (PBEF) and the enzyme nicotinamide phosphoribosyltransferase (Nampt). Enhanced circulating visfatin/Nampt levels have been reported in metabolic diseases, such as obesity and type 2 diabetes. Moreover, visfatin/Nampt circulating levels correlate with markers of systemic inflammation. In cardiovascular diseases, visfatin/Nampt was initially proposed as a clinical marker of atherosclerosis, endothelial dysfunction, and vascular damage, with a potential prognostic value. Nevertheless, beyond being a surrogate clinical marker, visfatin/Nampt is an active player promoting vascular inflammation, and atherosclerosis. Visfatin/Nampt effects on cytokine and chemokine secretion, macrophage survival, leukocyte recruitment by endothelial cells, vascular smooth muscle inflammation and plaque destabilization make of this adipokine an active factor in the development and progression of atherosclerosis. Further research is required to fully understand the mechanisms mediating the cellular actions of this adipokine and to better characterize the factors regulating visfatin/Nampt expression and release in all these pathologic scenarios. Only then, we will be able to conclude whether visfatin/Nampt is a therapeutical target in cardiometabolic diseases. Hindawi Publishing Corporation 2013 2013-06-16 /pmc/articles/PMC3697395/ /pubmed/23843684 http://dx.doi.org/10.1155/2013/946427 Text en Copyright © 2013 Tania Romacho et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Romacho, Tania Sánchez-Ferrer, Carlos F. Peiró, Concepción
spellingShingle	Romacho, Tania Sánchez-Ferrer, Carlos F. Peiró, Concepción Visfatin/Nampt: An Adipokine with Cardiovascular Impact
author_facet	Romacho, Tania Sánchez-Ferrer, Carlos F. Peiró, Concepción
author_sort	Romacho, Tania
title	Visfatin/Nampt: An Adipokine with Cardiovascular Impact
title_short	Visfatin/Nampt: An Adipokine with Cardiovascular Impact
title_full	Visfatin/Nampt: An Adipokine with Cardiovascular Impact
title_fullStr	Visfatin/Nampt: An Adipokine with Cardiovascular Impact
title_full_unstemmed	Visfatin/Nampt: An Adipokine with Cardiovascular Impact
title_sort	visfatin/nampt: an adipokine with cardiovascular impact
description	Adipose tissue is acknowledged as an endocrine organ that releases bioactive factors termed adipokines. Visfatin was initially identified as a novel adipokine with insulin-mimetic properties in mice. This adipokine was identical to two previously described molecules, namely, pre-B cell colony-enhancing factor (PBEF) and the enzyme nicotinamide phosphoribosyltransferase (Nampt). Enhanced circulating visfatin/Nampt levels have been reported in metabolic diseases, such as obesity and type 2 diabetes. Moreover, visfatin/Nampt circulating levels correlate with markers of systemic inflammation. In cardiovascular diseases, visfatin/Nampt was initially proposed as a clinical marker of atherosclerosis, endothelial dysfunction, and vascular damage, with a potential prognostic value. Nevertheless, beyond being a surrogate clinical marker, visfatin/Nampt is an active player promoting vascular inflammation, and atherosclerosis. Visfatin/Nampt effects on cytokine and chemokine secretion, macrophage survival, leukocyte recruitment by endothelial cells, vascular smooth muscle inflammation and plaque destabilization make of this adipokine an active factor in the development and progression of atherosclerosis. Further research is required to fully understand the mechanisms mediating the cellular actions of this adipokine and to better characterize the factors regulating visfatin/Nampt expression and release in all these pathologic scenarios. Only then, we will be able to conclude whether visfatin/Nampt is a therapeutical target in cardiometabolic diseases.
publisher	Hindawi Publishing Corporation
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697395/
_version_	1611990737192222720

Visfatin/Nampt: An Adipokine with Cardiovascular Impact

Similar Items